Lupin Q4 profit, US sales growth, and strong revenue momentum remained in focus after the pharmaceutical company reported an 87.7% jump in consolidated net profit to Rs 1,468.7 crore for the fourth quarter of FY2026. The impressive performance was mainly driven by strong demand in the US market, healthy growth in India, and improved operational efficiency across businesses.
The Mumbai-based drugmaker posted revenue from operations of Rs 7,391.9 crore during the January-March quarter, marking a 32.9% increase compared to Rs 5,562.2 crore in the same period last year. Lupin’s better product mix and higher sales in key markets helped the company deliver one of its strongest quarterly performances in recent years.
The company’s US business growth emerged as the biggest growth driver during the quarter. Revenue from the American market rose nearly 57% year-on-year to Rs 3,398.7 crore. The growth was supported by strong generic drug sales, new product launches, and a steady increase in market share. Meanwhile, domestic sales in India also remained healthy, growing 11.5% to Rs 1,908.2 crore.
Lupin also recorded a major improvement in profitability. EBITDA growth for the quarter surged to Rs 2,626.3 crore, while the EBITDA margin expanded to 35.5% from 24.8% a year earlier. Analysts believe the margin growth reflects stronger operational control, higher-value product sales, and favorable foreign exchange movements during the quarter.
Also Read: Chinese Cancer Drugs Bring Affordable Relief to Indian Patients
For the full financial year FY2026, Lupin reported consolidated net profit of Rs 5,355.5 crore, up 62% from the previous year. Annual revenue also increased nearly 24% to Rs 27,487.5 crore, highlighting sustained growth across its global pharmaceutical operations.
The company’s board recommended a dividend announcement of Rs 18 per equity share for FY2026, subject to shareholder approval. Managing Director Nilesh Gupta said Lupin remains focused on strengthening its global presence through technology investments, product innovation, and operational improvements.
Market experts believe the latest earnings highlight Lupin’s growing strength in the Indian pharmaceutical industry, especially in the highly competitive US generics market.
.jpg)
.jpg)
